Cozad Asset Management Inc. acquired a new stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 7,240 shares of the financial services provider’s stock, valued at approximately $795,000.

A number of other hedge funds also recently made changes to their positions in IBB. Natixis lifted its position in iShares Nasdaq Biotechnology ETF by 631.5% in the first quarter. Natixis now owns 1,150,000 shares of the financial services provider’s stock valued at $122,751,000 after purchasing an additional 992,783 shares during the last quarter. Paloma Partners Management Co increased its stake in shares of iShares Nasdaq Biotechnology ETF by 1,643.3% during the second quarter. Paloma Partners Management Co now owns 323,373 shares of the financial services provider’s stock valued at $35,513,000 after buying an additional 304,824 shares during the period. Commerzbank Aktiengesellschaft FI increased its stake in shares of iShares Nasdaq Biotechnology ETF by 54.0% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 585,506 shares of the financial services provider’s stock valued at $64,300,000 after buying an additional 205,200 shares during the period. Raymond James Financial Services Advisors Inc. purchased a new position in shares of iShares Nasdaq Biotechnology ETF during the second quarter valued at approximately $18,741,000. Finally, Cornerstone Wealth Management LLC purchased a new position in shares of iShares Nasdaq Biotechnology ETF during the second quarter valued at approximately $1,420,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

IBB opened at $117.77 on Friday. iShares Nasdaq Biotechnology ETF has a 52-week low of $100.22 and a 52-week high of $122.53.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading: Growth Stocks

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.